Arş. Gör. SİNEM ÖZÇELİK

Yayın Ağı

Makaleler 7

1. COVID-19 vaccine response in Neuromyelitis Optica Spectrum Disorder.

Baba C., Kaya E., Ozcelik S., Ozdogar A. T., Samedzade U., Cevik S., et al.

Clinical neurology and neurosurgery , cilt.238, sa.238, ss.108152, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

2. Three doses of COVID-19 vaccines in multiple sclerosis patients treated with disease-modifying therapies.

Baba C., Ozcelik S., Kaya E., Samedzada U., Ozdogar A. T., Cevik S., et al.

Multiple sclerosis and related disorders , cilt.68, ss.104119, 2022 (SCI-Expanded, Scopus)

3. Relationship between presence of spinal cord lesion and restless legs syndrome in multiple sclerosis

Baba C., Ozdogar A. T., ÖZÇELİK S., KAYA E., ÖZAKBAŞ S.

SOMATOSENSORY AND MOTOR RESEARCH , cilt.39, sa.2-4, ss.116-120, 2022 (SCI-Expanded)

4. Relationship Between Upper Extremity Functions and Gait in People with Multiple Sclerosis

Daştan S., Özçelik S., Yavaş İ., Özdoğar A. T.

Journal of Multiple Sclerosis Research , cilt.2, sa.2, ss.41-45, 2022 (Hakemli Dergi)

5. Awareness and Knowledge Levels of Osteoporosis in Patients with Multiple Sclerosis

Karakaş A., Erdinç Gündüz N., Özçelik S., Limoncu H., Dilek B., Gülbahar S., et al.

TURK OSTEOPOROZ DERGISI-TURKISH JOURNAL OF OSTEOPOROSIS , cilt.28, sa.2, ss.131-136, 2022 (ESCI, Scopus, TRDizin)

6. Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies

Özakbaş S., Baba C., Doğan Y., Cevik S., Özçelik S., Kaya E.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , cilt.58, 2022 (SCI-Expanded, Scopus)

7. The Efficacy of Fampridine on Upper Extremity Functions in Individuals with Multiple Sclerosis: Is There a Difference between Cerebellar and Pyramidal Dysfunction?

Ozdogar A. T., Ozcelik S., Dastan S.

Journal of Multiple Sclerosis Research , cilt.1, sa.1, ss.75-78, 2021 (Hakemli Dergi)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 21

1. Asymmetrical Neuroimaging Insights in CSF-Validated Early-Onset Alzheimer's: Integrating PET, MRI, and Cognitive Assessment

Özçelik S., Yiğit P., Bozdemir T. C., Çapa Kaya G., Yıldırım Z., Tee B. L., et al.

the Alzheimer’s Association International Conference, Pennsylvania, Amerika Birleşik Devletleri, 28 Temmuz - 01 Ağustos 2024, (Yayınlanmadı)

2. Correlation of Clinical and Imaging Findings in Early-Onset Alzheimer's Patients with Distinct Initial Symptoms

Özçelik S., Yiğit P., Bozdemir T. C., Çapa Kaya G., Yıldırım Z., Tee B. L., et al.

Alzheimer's Association International Conference, Pennsylvania, Amerika Birleşik Devletleri, 28 Temmuz - 01 Ağustos 2024, (Yayınlanmadı)

3. Effects of two grams of methylprednisolone in people with multiple sclerosis who received one gram of methylprednisolone for relapses

Alızada S., Özçelik S., Dastan S., Sagici O., Özdoğar A. T., Ozakbas S.

9th Joint ECTRIMS-ACTRIMS meeting, Milan, İtalya, 11 - 13 Ekim 2023, ss.1040, (Özet Bildiri)

4. Serum progranulin levels and cognitive function in people with multiple sclerosis: limited evidence for an association

KAYA E., Cevik S., Sagici O., ÖZÇELİK S., DOĞAN Y., Ozakbas S.

9th Joint ECTRIMS-ACTRIMS meeting, Milan, İtalya, 11 - 13 Ekim 2023, ss.902-903, (Özet Bildiri)

5. A comparison of cognitive batteries to assess cognitive impairment in multiple sclerosis

Yiğit P., Sağıcı Ö., Özçelik S., Abasıyanık Z., Kaya E., Baba C., et al.

The 9th Joint ECTRIMS-ACTRIMS Meeting, Milan, İtalya, 11 - 13 Ekim 2023, ss.102, (Özet Bildiri)

6. Efficacy of Original Fingolimod vs. Generic-Brand Drugs in Treating Multiple Sclerosis: A comparative Study Using Real-World Data from Turkey

Özçelik S., Sağıcı Ö., Özdoğar A. T., Kaya E., Özakbaş S.

The 9th Joint ECTRIMS-ACTRIMS Meeting, Milan, İtalya, 11 - 13 Ekim 2023, ss.292-293, (Özet Bildiri)

7. Physical and cognitive profile of elderly persons with multiple sclerosis and comparison with healthy controls

Özakbaş S., Özdoğar A. T., Baba C., Özçelik S., Kaya E., Sağıcı Ö.

ECTRIMS 2022, Amsterdam, Hollanda, 26 - 28 Ekim 2022, cilt.28, sa.821, ss.705, (Özet Bildiri)

8. Effects of ocrelizumab on disability progression and inflammatory activity in multiple sclerosis patients during the two-year follow-up

Özakbaş S., Baba C., Kaya E., Özçelik S., Özdoğar A. T., Daştan S.

ECTRIMS 2022, Amsterdam, Hollanda, 26 - 28 Ekim 2022, cilt.28, sa.1084, ss.862, (Özet Bildiri)

13. COVID-19 antibody response after two doses of SARS-CoV-2 vaccines in multiple sclerosis patients; an update to the previous study

Ozakbas S., Baba C., ÖZÇELİK S., Özdoğar A. T., KAYA E., DOĞAN Y., et al.

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Hollanda, 26 - 28 Ekim 2022, sa.922, ss.764-765, (Özet Bildiri)

14. Immune response against SARS-CoV-2 vaccines in treatment-naive multiple sclerosis patients

Ozakbas S., Baba C., SAMADZADE U., KAYA E., ÖZÇELİK S., Özdoğar A. T., et al.

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Hollanda, 26 - 28 Ekim 2022, sa.941, ss.776, (Özet Bildiri)